Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Epanutin

UK flag

UK sets aside £124m for health research projects

National Institute for Health Research to aims to revolutionise care

- PMLiVE

Pfizer sales dip as net income surges in Q2

Lipitor performance weighs heavy on the figures

- PMLiVE

GSK and Pfizer extend vaccine access programme

Pharma companies lower price of pneumococcal vaccines for developing nations

- PMLiVE

Pfizer separates branded and generic divisions

Follows spin out of animal health and nutrition

- PMLiVE

Pfizer and Otsuka face drug rejections in Europe

EMA turns down Xeljanz for rheumatoid arthritis and delamanid for tuberculosis

CytomX makes senior changes following Pfizer deal

Krishna Polu joins as chief medical officer and Debanjan Ray promoted to VP, business development

- PMLiVE

UK appoints chief inspector of adult social care

Andrea Sutcliffe to improve way the CQC regulates social care

- PMLiVE

The CementBloc strengthens its payer strategy expertise

The CementBloc boosts its US payer strategy team and capabilities to help US clients navigate shifting payer landscape

- PMLiVE

Pfizer wins Xeljanz approvals in five more countries

Switzerland, Argentina, Kuwait, United Arab Emirates and Russia to receive arthritis drug

- PMLiVE

AstraZeneca launches Nexium YouTube channel

New AZPurpleZone channel aimed at US patients with acid reflux disease offers symptom-relief advice and product savings

National Institute for Health and Care Excellence NICE logo

Pfizer faces NICE rejection for cancer drug Bosulif

Draft guidance says drug is not cost-effective in chronic myeloid leukaemia

EISAI

Eisai’s epilepsy drug Zonegran wins Swiss approval

Swissmedic licences new monotherapy indication for the treatment

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links